Study to Determine the Effects of Nebivolol and Hydrochlorothiazide in African Americans With Hypertension
NCT ID: NCT00999752
Last Updated: 2011-05-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
40 participants
INTERVENTIONAL
2009-10-31
2010-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Efficacy of Nebivolol in the Treatment of Hypertension in African Americans
NCT00145210
Dosing Study of the Effects of Nebivolol on Blood Pressure in Black Patients With Mild to Moderate Hypertension
NCT00145236
The Effect of Nebivolol on Endothelial Dysfunction in African Americans With Hypertension
NCT01049009
To Determine the Effect of Nebivolol on Office Blood Pressure of Blacks Residing in Nigeria
NCT03598673
Nebivolol in Patients With Systolic Stage 2 Hypertension
NCT01057251
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The study is to test whether or not Nebivolol (Bystolic)and a diuretic Hydrochlorothiazide (HCTZ) will help the heart relax so the heart can properly fill and prevent stiffness of the lower heart chambers.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm A
Nebivolol to reach blood pressure control
Nebivolol
5mg/day with increase to 10 mg/day to reach blood pressure \<140/90
Arm B
Hydrochlorothiazide for blood pressure control
Hydrochlorothiazide
Hydrochlorothiazide 25 mg/day
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Nebivolol
5mg/day with increase to 10 mg/day to reach blood pressure \<140/90
Hydrochlorothiazide
Hydrochlorothiazide 25 mg/day
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Self-described African American
Exclusion Criteria
* Known CAD, Cerebrovascular Disease, PVD or Renovascular Disease
* Liver disease
* Chronic Renal Disease
* Uncontrolled Hypertension (\>199 systolic and/or \>115)
18 Years
75 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
InVasc Therapeutics, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
InVasc Therapeutics, Inc.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bobby V Khan, MD PhD
Role: PRINCIPAL_INVESTIGATOR
InVasc Therapeutics, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Atlanta Vascular Research Foundation
Tucker, Georgia, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AVR-2009-02 (BYS-MD-27)
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.